The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin
Abstract
BACKGROUND: Women with polycystic ovary syndrome (PCOS) have an increased prevalence of insulin resistance (IR) and related disorders. Elevated serum levels of cellular adhesion molecules (CAMs) reflect low-grade chronic inflammation and have been associated with several insulin-resistant states. The objective of this study is to investigate whether soluble inflammatory markers [soluble intercellular adhesion molecule-1 (sICAM-1), soluble endothelial leukocyte adhesion molecule-1 (sE-selectin), soluble vascular cell adhesion molecule-1 (sVCAM-1) and C-reactive protein (CRP)] are altered in PCOS and to further elucidate the effect of metformin treatment on their levels. METHODS: Two young populations were studied [62 women with PCOS and 45 normal women of similar age, BMI and waist-to-hip ratio (WHR)]. Plasma levels of sICAM-1, sVCAM-1, sE-selectin and high-sensitivity CRP (hsCRP) were measured in both groups. Additionally, the effect of metformin on these molecules was investigated in 22 women with PCOS who accepted to metformin protocol (1700 mg daily for a 6-month period). RESULTS: In the total population studied, plasma levels of hsCRP (mg/l), sICAM-1 (ng/ml) and sE-selectin (ng/ml) were higher in the PCOS group compared with those in controls (hsCRP 1.31 +/- 0.22 versus 0.92 +/- 0.27, P = 0.014, sICAM-1 301.21 +/- 24.80 versus 209.86 +/- 17.05, P = 0.025, sE-selectin 57.37 +/- 4.08 versus 45.67 +/- 4.62, P = 0.045, respectively). sVCAM-1 (ng/ml) did not differ statistically among the two groups (P = 0.896). A significant reduction in hsCRP and sVCAM-1 was achieved after 6 months of metformin administration: PCOS pretreatment hsCRP 1.92 +/- 0.60 versus PCOS post-treatment hsCRP 0.52 +/- 0.26, P = 0.005; PCOS pretreatment sVCAM-1 668.09 +/- 98.38 versus PCOS post-treatment sVCAM-1 365.82 +/- 99.77, P = 0.039. CONCLUSION: These findings imply the presence of chronic inflammation in women with PCOS. Metformin decreases the levels of plasma inflammatory indices. Further investigation is required to determine whether these findings may prove to be of clinical significance for PCOS patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Inflammation, Atherosclerosis, and Coronary Artery Disease
Hansson, G. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043430 · Cited by 8,773
Ridker, P. M., Hennekens, C. H., Buring, J. E., & Rifai, N. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003233421202 · Cited by 5,850 · cited 2×
“In the last decade, markers of low-grade inflammation and certain components of the haemostatic system have been found to predict atherosclerotic risk (Ridker et al., 2000; Danesh et al., 2004) in IR states such as metabolic syndrome and T2D.”
Katz, A., Nambi, S. S., Mather, K., Baron, A. D., Follmann, D. A., Sullivan, G., & Quon, M. J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.7.6661 · Cited by 3,931 · cited 1×
“QUICKI is defined as: QUICKI = 1/[log ( fasting insulin) + log (fasting glucose)] (Katz et al., 2000 ).”
Danesh, J., Wheeler, J. G., Hirschfield, G. M., Eda, S., Eiriksdottir, G., Rumley, A., Lowe, G. D. O., Pepys, M. B., & Gudnason, V. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032804 · Cited by 2,953
Insulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for Pathogenesis*
Dunaif, A. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.6.0318 · Cited by 2,458
Ridker, P. M., Buring, J. E., Cook, N. R., & Rifai, N. (2003) · Circulation · doi:10.1161/01.cir.0000055014.62083.05 · Cited by 2,292
Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.
Ehrmann, D. A., Barnes, R. B., Rosenfield, R. L., Cavaghan, M. K., & Imperial, J. (1999) · Diabetes Care · doi:10.2337/diacare.22.1.141 · Cited by 1,257 · cited 8×
“…the most common endocrinopathy of reproductive age (Diamanti-Kandarakis et al., 1999), which is characterized by anovulation, hyperandrogenaemia and, frequently, insulin resistance (IR) represents a disorder with increased risk for type 2 diabetes (T2D) (Ehrmann et al., 1999; Orio et al., 2004).”
InfluentialA major role for VCAM-1, but not ICAM-1, in early atherosclerosis
Cybulsky, M. I., Iiyama, K., Li, H., Zhu, S., Chen, M., Iiyama, M., Davis, V., Gutierrez-Ramos, J.-C., Connelly, P. W., & Milstone, D. S. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11871 · Cited by 1,217
Cited by
Norman, R. J., Dewailly, D., Legro, R. S., & Hickey, T. E. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61345-2 · Cited by 1,360
Chronic Low Grade Inflammation in Pathogenesis of PCOS
Rudnicka, E., Suchta, K., Grymowicz, M., Calik-Ksepka, A., Smolarczyk, K., Duszewska, A. M., Smolarczyk, R., & Meczekalski, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073789 · Cited by 680
Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis
Escobar-Morreale, H. F., Luque-Ramírez, M., & González, F. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2010.11.036 · Cited by 517
Ovulation: Parallels With Inflammatory Processes
Duffy, D. M., Ko, C., Jo, M., Brannstrom, M., & Curry, T. E. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00075 · Cited by 513
Palomba, S., Falbo, A., Zullo, F., & Orio, F. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0030 · Cited by 426
Spritzer, P. M., Lecke, S. B., Satler, F., & Morsch, D. M. (2015) · Reproduction · doi:10.1530/rep-14-0435 · Cited by 330
Roles of oxidative stress in polycystic ovary syndrome and cancers
Zuo, T., Zhu, M., & Xu, W. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/8589318 · Cited by 319
Pathophysiology and types of dyslipidemia in PCOS
Diamanti-Kandarakis, E., Papavassiliou, A. G., Kandarakis, S. A., & Chrousos, G. P. (2007) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2007.07.004 · Cited by 299
Self-citationThe role of low-grade inflammation in the polycystic ovary syndrome
Repaci, A., Gambineri, A., & Pasquali, R. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.08.002 · Cited by 298
Polycystic ovarian syndrome: Pathophysiology, molecular aspects and clinical implications
Diamanti-Kandarakis, E. (2008) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399408000598 · Cited by 294
Self-citationElkind-Hirsch, K., Marrioneaux, O., Bhushan, M., Vernor, D., & Bhushan, R. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0115 · Cited by 276
Polycystic ovary syndrome and mitochondrial dysfunction
Zhang, J., Bao, Y., Zhou, X., & Zheng, L. (2019) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-019-0509-4 · Cited by 258
Jamilian, M., Mansury, S., Bahmani, F., Heidar, Z., Amirani, E., & Asemi, Z. (2018) · Journal of Ovarian Research · doi:10.1186/s13048-018-0457-1 · Cited by 156
Wei, W., Zhao, H., Wang, A., Sui, M., Liang, K., Deng, H., Ma, Y., Zhang, Y., Zhang, H., & Guan, Y. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-0616 · Cited by 155
Banaszewska, B., Pawelczyk, L., Spaczynski, R. Z., Dziura, J., & Duleba, A. J. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1988 · Cited by 143
de Jager, J., Kooy, A., Schalkwijk, C., van der Kolk, J., Lehert, P., Bets, D., Wulffelé, M. G., Donker, A. J., & Stehouwer, C. D. A. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12128 · Cited by 129
Indices of low-grade inflammation in polycystic ovary syndrome
DIAMANTI‐KANDARAKIS, E., PATERAKIS, T., & KANDARAKIS, H. A. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1365.015 · Cited by 112
Self-citationOkun, M. L., Luther, J. F., Wisniewski, S. R., & Wisner, K. L. (2013) · Psychosomatic Medicine · doi:10.1097/psy.0b013e31829cc3e7 · Cited by 94
“Low-grade chronic inflammation is a risk factor for various adverse health outcomes including cardiovascular disease, metabolic syndrome (51,58Y63) depression (64), sleep apnea (65Y68), polycystic ovarian syndrome (69,70), and obesity (69,71,72).”
BackgroundTosi, F., Di Sarra, D., Kaufman, J.-M., Bonin, C., Moretta, R., Bonora, E., Zanolin, E., & Moghetti, P. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2786 · Cited by 70
Teede, H. J., Meyer, C., Hutchison, S. K., Zoungas, S., McGrath, B. P., & Moran, L. J. (2010) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.09.034 · Cited by 68
Diamanti‐Kandarakis, E., Katsikis, I., Piperi, C., Alexandraki, K., & Panidis, D. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02693.x · Cited by 69
“The PCOS group pretreatment did not differ compared with the control group in GLU at 0 min, GLU at 120 min, INS, GIR, HOMA 106 E. Diamanti-Kandarakis et al. © 2006 The Authors Journal compilation © 2006 Blackwell Publishing Ltd, Clinical Endocrinology , 66 , 103–109 and QUICKI (P = 0·92, P = 0·65,…”
BackgroundResultInfluentialSelf-citationVictor, V. M., Rovira-Llopis, S., Bañuls, C., Diaz-Morales, N., Lopez-Domenech, S., Escribano-López, I., Rios-Navarro, C., Alvarez, A., Gomez, M., Rocha, M., et al. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.07.017 · Cited by 44
Nylander, M., Frøssing, S., Kistorp, C., Faber, J., & Skouby, S. O. (2017) · Endocrine Connections · doi:10.1530/ec-16-0113 · Cited by 44
Esfahanian, F., Zamani, M. M., Heshmat, R., & Moini nia, F. (2013) · Journal of obstetrics and gynaecology research · doi:10.1111/j.1447-0756.2012.02051.x · Cited by 38
Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS
Cignarella, A., Mioni, R., Sabbadin, C., Dassie, F., Parolin, M., Vettor, R., Barbot, M., & Scaroni, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249554 · Cited by 36
Risk of Cardiovascular Events in Mothers of Women with Polycystic Ovary Syndrome
Cheang, K. I., Nestler, J. E., & Futterweit, W. (2008) · Endocrine Practice · doi:10.4158/ep.14.9.1084 · Cited by 31
Javed, Z., Papageorgiou, M., Madden, L. A., Rigby, A. S., Kilpatrick, E. S., Atkin, S. L., & Sathyapalan, T. (2020) · Endocrine Connections · doi:10.1530/ec-20-0173 · Cited by 24
Xia, Y., Wang, Y., Cui, M., & Su, D. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-21-1050 · Cited by 23
Metadata
- Authors
- Diamanti-Kandarakis, E., Paterakis, T., Alexandraki, K., Piperi, C., Aessopos, A., Katsikis, I., Katsilambros, N., Kreatsas, G., & Panidis, D.
- Venue
- Human Reproduction
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-02-23
- Volume
- 21
- Issue
- 6
- Pages
- 1426-1431
- ISSN
- 0268-1161 (ISSN-L)
- 1460-2350
- OpenAlex
- W2148804426
- Cited by
- 258
- References
- 66
- FWCI
- 20.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.